Glomerulonephritis

Displaying 8 studies

  • Characteristics of Fibrillary Glomerulonephritis Rochester, MN

    This study will characterize disease symptons as well as pathology related to proteins for fibrillary glomerulonephritis (FGN).

  • Pilot Study of Rituximab to Treat Fibrillary Glomerulonephritis Rochester, MN

    Will use of Rituximab reduce proteinuria over a 12 month period and will there be preservation of kidney function with the use of this study drug?

  • Controlled Trial Evaluating Avacopan in C3 Glomerulopathy Rochester, MN

    The aim of this trial is to evaluate the effect of avacopan treatment on renal disease activity in patients with complement component 3 glomerulopathy (C3G).

  • Evaluation of Laboratory Methods for Detecting Auto Antibodies to Complement Proteins Rochester, MN

    The goal of this study is to validate testing to be performed in the clinical immunology lab and have a source of positive patient sera.

    These tests include:

    1. Auto antibodies to Factor H
    2. C3 Nephritic Factor
    3. Auto antibodies to C1q
    4. Auto antibodies to C1INH

  • Podocyturia in Diabetes Mellitus Type 2 and Proteinuric Glomerulonephritides Rochester, MN

    The goal of this study is to evaluate the presence of podocytes (special cells in the kidney that prevent protein loss) in the urine in patients with diabetes or glomerulonephritis (inflammation in the kidneys). Loss of podocyte in the urine may be an earlier sign of kidney injury (before protein loss) and the goal of this study is to evaluate the association between protein in the urine and podocytes in the urine.

  • Mutational Analysis of Alternative Pathway Complement Regulatory Proteins Rochester, MN

    The purpose of this study is to develop and validate full gene-sequencing assays or known mutation sequencing assays for the evaluation of patients with suspected alternative pathway complement defects. 

  • Open-label Trial of Daratumumab in Treatment of PGNIMD and C3 GN Rochester, MN

    This study is being done to see if daratumumab is safe and effective in the treatment of proliferative glomerulonephritis with monoclonal immune deposits (PGNMID) and C3 glomerulopathy associated with monoclonal gammopathy (C3GN). This is an inflammatory disease in the kidney due to the production of abnormal proteins. There are no known standard effective treatments for patients with PGNMID and C3GN secondary to monoclonal gammopathy. These diseases are caused by abnormal production of proteins (monoclonals) by abnormal clones. Daratumamb has been shown to be effective in treating patients with multiple myeloma a disease which also caused by over production of monoclonal ...

  • Mayo Clinic Superspecialty Telemedicine Consultation Pilot Study Rochester, MN

    The overall objective of this project is to determine the feasibility of implementing a superspecialist consult model between Mayo Clinic and UMMC in the field of OB nephrology in 20 participants who are ≥ 18 years of age. 

     

     

.

Mayo Clinic Footer